Preclinical evaluation of a promising C-11 labeled PET tracer for imaging phosphodiesterase 10A in the brain of living subject

Phosphodiesterase 10A (PDE10A) plays a key role in the regulation of brain striatal signaling. A PET tracer for PDE10A may serve as a tool to evaluate PDE10A expression in vivo in central nervous system disorders with striatal pathology. Here, we further characterized the binding properties of a previously reported radioligand we developed for PDE10A, [(11)C]TZ1964B, in rodents and nonhuman primates (NHPs). The tritiated counterpart [(3)H]TZ1964B was used for in vitro binding characterizations in rat striatum homogenates and in vitro autoradiographic studies in rat brain slices. The carbon-11 labeled [(11)C]TZ1964B was utilized in the ex vivo autoradiography studies for the brain of rats and microPET imaging studies for the brain of NHPs. MicroPET scans of [(11)C]TZ1964B in NHPs were conducted at baseline, as well as with using a selective PDE10A inhibitor MP-10 for either pretreatment or displacement. The in vivo regional target occupancy (Occ) was obtained by pretreating with different doses of MP-10 (0.05-2.00 mg/kg). Both in vitro binding assays and in vitro autoradiographic studies revealed a nanomolar binding affinity of [(3)H]TZ1964B to the rat striatum. The striatal binding of [(3)H]TZ1964B and [(11)C]TZ1964B was either displaced or blocked by MP-10 in rats and NHPs. Autoradiography and microPET imaging confirmed that the specific binding of the radioligand was found in the striatum but not in the cerebellum. Blocking studies also confirmed the suitability of the cerebellum as an appropriate reference region. The binding potentials (BPND) of [(11)C]TZ1964B in the NHP striatum that were calculated using either the Logan reference model (LoganREF, 3.96 ± 0.17) or the simplified reference tissue model (SRTM, 4.64 ± 0.47), with the cerebellum as the reference region, was high and had good reproducibility. The occupancy studies indicated a MP-10 dose of 0.31 ± 0.09 mg/kg (LoganREF)/0.45 ± 0.17mg/kg (SRTM) occupies 50% striatal PDE10A binding sites. Studies in rats and NHPs demonstrated radiolabeled TZ1964B has a high binding affinity and good specificity for PDE10A, as well as favorable in vivo pharmacokinetic properties and binding profiles. Our data suggests that [(11)C]TZ1964B is a promising radioligand for in vivo imaging PDE10A in the brain of living subject.

[1]  R. Parsey,et al.  Reference Region Approaches in PET: a Comparative Study on Multiple Radioligands , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  Yoshiro Okubo,et al.  High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. , 2003, Archives of general psychiatry.

[3]  Richard E Carson,et al.  Further evaluation of [11C]MP‐10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis , 2015, Synapse.

[4]  Anil Kumar,et al.  Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography , 2013, NeuroImage.

[5]  Jinbin Xu,et al.  [3H]4‐(dimethylamino)‐N‐(4‐(4‐(2‐methoxyphenyl)piperazin‐1‐yl) butyl)benzamide: A selective radioligand for dopamine D3 receptors. II. Quantitative analysis of dopamine D3 and D2 receptor density ratio in the caudate‐putamen , 2010, Synapse.

[6]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  Joel S Perlmutter,et al.  Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. , 2011, Bioorganic & medicinal chemistry.

[8]  Richard E Carson,et al.  Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. , 2011, Nuclear medicine and biology.

[9]  Jerry Lanfear,et al.  Immunohistochemical localization of PDE10A in the rat brain , 2003, Brain Research.

[10]  Mark Schmidt,et al.  Preclinical evaluation of [18F]JNJ42259152 as a PET tracer for PDE10A , 2013, NeuroImage.

[11]  Mark Slifstein,et al.  Initial characterization of a PDE10A selective positron emission tomography tracer [11C]AMG 7980 in non-human primates. , 2014, Nuclear medicine and biology.

[12]  Olivier Barret,et al.  First in vivo assessment of two PDE10 tracers [18F]MNI654 and [18F]MNI659 , 2012 .

[13]  Koen Van Laere,et al.  Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Christer Halldin,et al.  Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A. , 2015, Nuclear medicine and biology.

[15]  Robert H Mach,et al.  Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. , 2010, Nuclear medicine and biology.

[16]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  H Watabe,et al.  Noninvasive Quantification of rCBF Using Positron Emission Tomography , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  R. D. Williams,et al.  Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase , 2006, Neuroscience.

[19]  Koen Van Laere,et al.  Quantification of 18F-JNJ-42259152, a Novel Phosphodiesterase 10A PET Tracer: Kinetic Modeling and Test–Retest Study in Human Brain , 2013, The Journal of Nuclear Medicine.

[20]  Yi Su,et al.  Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate. , 2014, Bioorganic & medicinal chemistry.

[21]  J. Mazziotta,et al.  MRI‐PET Registration with Automated Algorithm , 1993, Journal of computer assisted tomography.

[22]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[23]  Olivier Barret,et al.  In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: 18F-MNI-659 and 18F-MNI-654 , 2014, The Journal of Nuclear Medicine.

[24]  F. Menniti,et al.  PDE10A: A Striatum-Enriched, Dual-Substrate Phosphodiesterase , 2006 .

[25]  Lin Xie,et al.  PET brain kinetics studies of (11)C-ITMM and (11)C-ITDM,radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate. , 2014, American journal of nuclear medicine and molecular imaging.

[26]  Tom R. Miller,et al.  Interactive reconstruction in single-photon tomography , 2004, European Journal of Nuclear Medicine.

[27]  A. Nishi,et al.  Mechanisms for the Modulation of Dopamine D1 Receptor Signaling in Striatal Neurons , 2011, Front. Neuroanat..

[28]  Gunnar Antoni,et al.  Discovery and Development of 11C-Lu AE92686 as a Radioligand for PET Imaging of Phosphodiesterase10A in the Brain , 2014, The Journal of Nuclear Medicine.

[29]  J. Beavo,et al.  Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[31]  M. Trevethick,et al.  Ligand binding assays at equilibrium: validation and interpretation , 2010, British journal of pharmacology.

[32]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[33]  Koen Van Laere,et al.  Preclinical Evaluation of 18F-JNJ41510417 as a Radioligand for PET Imaging of Phosphodiesterase-10A in the Brain , 2010, The Journal of Nuclear Medicine.

[34]  Haiying Zhou,et al.  Synthesis and in vitro biological evaluation of pyrazole group-containing analogues for PDE10A. , 2013, MedChemComm.

[35]  Christopher J Helal,et al.  Current landscape of phosphodiesterase 10A (PDE10A) inhibition. , 2012, Journal of medicinal chemistry.